Andrew ElBardissi

Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California.

NeoChord, Inc. develops medical devices. It offers NeoChord, a disposable device that replaces damaged chordae through a small incision while the heart is beating. The company was founded in 2007 and is headquartered in St. Louis Park, MN.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA.

V-Wave Ltd. engages in the development of implantable medical device for treating chronic heart failure. It offers V-Wave Shunt, which is a biocompatible inter-atrial unidirectional implant. The company was founded by Gad Keren and Yaacov Nitzan in 2009 and is headquartered in Caesarea, Israel.

Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY.

Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York.

CathWorks Ltd. develops medical devices for the interventional cardiology market. Its technology is based on processing visual information and automatic multi-layered algorithms. The company was founded by Guy Lavi and Ifat Lavi in 2013 and is headquartered in Raanana, Israel.

MTrap, Inc. engages in the development of novel therapeutic devices that interfere with the intense dialogue and crosstalk between the primary tumor and the microenvironment and represent a new disruptive approach to cancer treatment. The company was founded by Maybelle L. Jordan and is headquartered in Huntington, NY.

Medical Microinstruments SpA develops and manufactures surgical micro-instruments. The firm focuses on clinical outcomes for patients undergoing microsurgery, and offers advanced microsurgical procedures, while reducing costs for patients, hospitals and for society at large. The company was founded by Giuseppe Prisco, Hannah Teichmann and Massimiliano Simi in 2015 and is headquartered in Calci, Italy.

Mount Sinai Genomics, Inc. operates online predictive health analysis platform for diagnosis, treatment and prevention of diseases. It offers Centrellis which analyzes and interprets extensive information about known inherited diseases, including related mutations, frequency across populations, and the penetrance and expressivity of genetic changes. The company was founded by Eric Schadt and is headquartered in Stamford, CT.

Encodia, Inc. engages in the research and development of protein analysis tools. The company was founded by Mark S. Chee, Michael Weiner, and Kevin Gunderson and is headquartered in San Diego, CA.

Reprieve Cardiovascular, Inc. engages in the manufacturing of medical devices. The firm develops device to treat patients suffering from acute decompensated heart failure (ADHF). The company is headquartered in Milford, MA.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Pleno, Inc. is a company that specializes in multi-omic instrument platform technology for clinical testing and biomedical research. The company is based in San Diego, CA and was founded by Pieter van Rooyen, who has been the CEO since incorporation. The company's proprietary hypercoding™ technology uses signal processing techniques to provide targeted biological information with exceptional scale, precision, and performance.

DA32 Life Science Tech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on April 16, 2021 and is headquartered in New York, NY.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.